XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Cash flows from operating activities:      
Net loss $ (79,073,719) $ (54,402,131)  
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation 929,383 660,697  
Amortization of intangible assets 126,770 136,770  
Amortization of operating lease right-of-use assets 319,586 278,290  
Stock-based compensation 7,711,151 9,595,947  
Non-cash interest expense (219,999) (31,281)  
Amortization of premiums on investments 125,810 0  
Loss on short-term investments 318,684 10,151  
Loss on disposal of fixed assets 157,666 0  
Gain on remeasurement of investment in Geneos (165,215) 0  
Loss on equity investment in affiliated entities 537,728 830,475  
Share of net loss in Geneos 2,165,213 434,387  
Net unrealized loss on available-for-sale equity securities 4,840,641 847,958  
Unrealized transaction loss on foreign-currency denominated debt 0 (176,927)  
Changes in operating assets and liabilities:      
Accounts receivable, including from affiliated entities 541,248 8,804,853  
Prepaid expenses and other current assets, including from affiliated entities 7,075,934 (19,108,348)  
Other assets 151,999 75,514  
Accounts payable and accrued expenses (9,859,913) 4,735,352  
Accrued clinical trial expenses 1,501,489 (2,579,476)  
Accounts payable and accrued expenses due to affiliated entities 859,354 125,292  
Deferred revenue, including from affiliated entity (9,963) (72,463)  
Operating lease right-of-use assets and liabilities, net (624,673) (558,140)  
Grant funding liability, including from affiliated entity 723,550 (2,480,826)  
Other liabilities (14,826) 6,478  
Net cash used in operating activities (61,882,102) (52,867,428)  
Cash flows from investing activities:      
Purchases of investments (99,722,697) (275,408,976)  
Proceeds from sale or maturity of investments 123,055,048 504,464  
Purchases of capital assets 0 (210,824)  
Investment in Geneos (1,999,998) 0  
Net cash provided by (used in) investing activities 21,332,353 (275,115,336)  
Cash flows from financing activities:      
Proceeds from issuance of common stock, net of issuance costs 29,364,538 162,105,030  
Proceeds from stock option exercises 83,812 2,632,996  
Taxes paid related to net share settlement of equity awards (1,026,333) (3,834,785)  
Net cash provided by financing activities 28,422,017 160,903,241  
Effect of exchange rate changes on cash and cash equivalents (6,555) (14,419)  
Decrease in cash and cash equivalents (12,134,287) (167,093,942)  
Cash and cash equivalents, beginning of period 71,143,778 250,728,118 $ 250,728,118
Cash and cash equivalents, end of period 59,009,491 83,634,176 $ 71,143,778
Supplemental disclosures:      
Amounts accrued for purchases of fixed assets 330,779 35,370  
Interest paid $ 533,487 $ 544,315